TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1649288

Group type: EXPERIMENTAL
Intervention: TPN solution with Ca:P ratio of 2:1 (76 mg/kg/day Ca and 38 mg/kg/day P)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TPN solution with Ca:P ratio of 1.3:1 (58 mg/kg/day Ca and 45 mg/kg/day P)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TPN solution with Ca:P ratio of 1.7:1
Number of subjects: 41

Group type: COMPARATOR
Intervention: TPN solutions with all ratios (2:1, 1.3:1, and 1.7:1)
Number of subjects: 41
Study: 6876443

Group type: EXPERIMENTAL
Intervention: Whole brain irradiation using 4 MV X-ray
Number of subjects: 40
Study: 30812035

Group type: EXPERIMENTAL
Intervention: Spaced learning concept
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 20
Study: 31356229

Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg twice daily for 12 weeks
Number of subjects: 346
Study: 27976833

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27059971

Group type: EXPERIMENTAL
Intervention: 3D robotic surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3D straight-stick laparoscopy
Number of subjects: 20
Study: 24552317

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study: 22934497

Group type: EXPERIMENTAL
Intervention: Reversal high-speed air turbine extraction with appropriate nursing interventions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional chisel splint method
Number of subjects: 60
Study: 19210948

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean daily dosage 10.6 mg/day)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study: 17554255

Group type: EXPERIMENTAL
Intervention: Nutrineal (AA source) plus Physioneal (glucose) dialysate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physioneal alone dialysate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral protein intake
Number of subjects: 20
Study: 15812097

Group type: EXPERIMENTAL
Intervention: Outpatient services for general medical problems
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Dental and vision services
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Screening tests for women (mammograms and pap tests)
Number of subjects: 669
Study: 12230333

Group type: EXPERIMENTAL
Intervention: Postcontraction condition (3-s isometric contraction of knee extensor muscles prior to auditory stimulus)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition (learned rapid knee-extension contraction response to auditory stimulus)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postcontraction condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study: 9475531

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 7889238

Group type: EXPERIMENTAL
Intervention: Aspirin (various dosages)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Aspirin (25 mg/day increase)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lower doses of aspirin
Number of subjects: 36
Study: 2225560

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (6 months), dipyridamole and warfarin (2 years)
Number of subjects: 52
Study: 30767

Group type: EXPERIMENTAL
Intervention: Lorazepam (3 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30999897

Group type: EXPERIMENTAL
Intervention: TeaCrine®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TeaCrine® + caffeine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28603054

Group type: EXPERIMENTAL
Intervention: 1-minute EPBD
Number of subjects: 170

Group type: COMPARATOR
Intervention: 5-minute EPBD
Number of subjects: 170
Study: 25762758

Group type: EXPERIMENTAL
Intervention: Menthol tobacco-flavored e-cigarette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-menthol tobacco-flavored e-cigarette
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preferred flavor by sex interaction
Number of subjects: 20
Study: 24114461

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg single dose
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg single dose
Number of subjects: 66
Study: 21696615

Group type: EXPERIMENTAL
Intervention: Individually integrated TCM approach (oral counter osteophytes capsule, variable use of Tuina, acupuncture, and herbal patch) for 4 weeks
Number of subjects: 500

Group type: COMPARATOR
Intervention: Oral administration of a Chinese herbal drug (counter osteophytes capsule) for 4 weeks
Number of subjects: 500

Group type: COMPARATOR
Intervention: Topical use of a Chinese herbal patch (Fufnag Zijin patch) for 4 weeks
Number of subjects: 500

Group type: COMPARATOR
Intervention: Acupuncture for 4 weeks
Number of subjects: 500

Group type: COMPARATOR
Intervention: Tuina for 4 weeks
Number of subjects: 500
Study: 19426239

Group type: EXPERIMENTAL
Intervention: S-LMA
Number of subjects: 60

Group type: COMPARATOR
Intervention: P-LMA
Number of subjects: 60
Study: 16961716

Group type: EXPERIMENTAL
Intervention: Levocetirizine (LCZ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11880823

Group type: EXPERIMENTAL
Intervention: 30% 1-RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 60% 1-RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 90% 1-RM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood lactate concentration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EMG activity
Number of subjects: 20
Study: 10456699

Group type: EXPERIMENTAL
Intervention: Vascular Clipping System (VCS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) suturing
Number of subjects: 96
Study: 7598053

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (50 mg radiolabeled ferrous sulfate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (50 mg radiolabeled ferrous sulfate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Daily iron supplementation
Number of subjects: 23
Study: 2219842

Group type: EXPERIMENTAL
Intervention: Neutron beam therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Combined treatment (radiation + surgery)
Number of subjects: 52
Study: 352706

Group type: EXPERIMENTAL
Intervention: Molsidomine (2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30024323

Group type: EXPERIMENTAL
Intervention: 8 h in bed overnight with a 1‐h daytime nap (8 h + 1 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7 h in bed overnight with a 2‐h daytime nap (7 h + 2 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 9 h in bed overnight with no daytime nap (9 h + 0 h)
Number of subjects: 12
Study: 25754188

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine solution (10 ml 8.4% sodium bicarbonate + 20 ml 2% lidocaine solution + 22 ml sterile Aquagel®)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lidocaine gel (22 ml standard 2% lidocaine gel Instillagel® + 30 ml 0.9% normal saline solution)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine solution
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lidocaine gel
Number of subjects: 54
Study: 24824893

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1079
Study: 23567060

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intravenously + Diphenhydramine 25 mg intravenously
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketorolac 30 mg intravenously
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide + Diphenhydramine
Number of subjects: 120
Study: 22748030

Group type: EXPERIMENTAL
Intervention: Eclectic approach therapy with parental involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist-led treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-led treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated children
Number of subjects: 0
Study: 17379359

Group type: EXPERIMENTAL
Intervention: Galantamine (16-24mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15719316

Group type: EXPERIMENTAL
Intervention: TGDc‐01 PRA
Number of subjects: 225

Group type: COMPARATOR
Intervention: Goldmann tonometry
Number of subjects: 225
Study: 11834534

Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Extracted soy protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-selected to soy protein diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Extracted soy protein and casein diets
Number of subjects: 12
Study: 9799062

Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg divided into 2 doses (twice-daily)
Number of subjects: 0
Study: 7542465

Group type: EXPERIMENTAL
Intervention: Culturally sensitive video education intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Culturally dissimilar video education intervention
Number of subjects: 194
Study: 2677721

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day) in reactive patients
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group in reactive patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day) in nonreactive patients
Number of subjects: 102
Study: 72239

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (S.A.S.P.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-A.S.A.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphapyridine (S.P.)
Number of subjects: 0
Study: 31745991

Group type: EXPERIMENTAL
Intervention: Lasmiditan 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alprazolam 2 mg
Number of subjects: 0
Study: 31206639

Group type: EXPERIMENTAL
Intervention: Explicit prognostic disclosure (video with explicit disclosure)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Nondisclosure (video without explicit disclosure)
Number of subjects: 105
Study: 27859312

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting central lymph node metastasis (CLNM)
Number of subjects: 10763
Study: 25922846

Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic drugs and vitamin D3 therapy (Group DM4)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (Group DM3)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (Group NC)
Number of subjects: 145
Study: 24666922

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin bolus (hypoglycaemia)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Euglycaemia (control episode)
Number of subjects: 10
Study: 21246365

Group type: EXPERIMENTAL
Intervention: Active and passive physiotherapy methods
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active treatment methods
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (nonsteroid anti-inflammatory and muscle relaxing medicines)
Number of subjects: 60
Study: 19634042

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin gel 0.025%
Number of subjects: 0
Study: 17323096

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel and fibrin sealant
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no platelet gel and fibrin sealant)
Number of subjects: 165
Study: 15247958

Group type: EXPERIMENTAL
Intervention: ASKEnox (n=165): Enox 40 mg i.v. followed by SK 1.5 MU over 20 min, Enox 1 mg/kg s.c. every 12 hours for 5-7 days
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: ASKUFH (n=264): Same as ASKEnox plus UFH 1,000 IU/h for 48-72 hours
Number of subjects: 633

Group type: COMPARATOR
Intervention: SSKUFH (n=204): SK 1.5 MU/60 min plus UFH 1,000 IU/h for 48-72 hours
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: ASKEnox
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: ASKUFH
Number of subjects: 633

Group type: COMPARATOR
Intervention: SSKUFH
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: ASKEnox and ASKUFH
Number of subjects: 633
Study: 11746315

Group type: EXPERIMENTAL
Intervention: Weighting methods derived using linear regression on overall quality of life measures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedures for transforming quality of life measures into utility measures.
Number of subjects: 0
Study: 9645976

Group type: EXPERIMENTAL
Intervention: CORTI
Number of subjects: 3

Group type: COMPARATOR
Intervention: SDI
Number of subjects: 3

Group type: COMPARATOR
Intervention: PICH
Number of subjects: 3
Study: 7528302

Group type: EXPERIMENTAL
Intervention: 5-HT (0.1, 0.3, and 1 ng/kg/min) with L-NMMA (30 μg/kg/min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flesinoxan (15, 45, and 150 ng/kg/min) with L-NMMA (30 μg/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline with L-NMMA (30 μg/kg/min)
Number of subjects: 8
Study: 29771966

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) ingestion up to 150 mg∙kg‐1 in a progressive-dose regimen for 10 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB) ingestion
Number of subjects: 21
Study: 26418574

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 536 (BB536)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24748529

Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE) at 150% VO2 peak for 30 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON) cycling at 50% VO2 peak for 30 minutes
Number of subjects: 8
Study: 23735118

Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 19690913

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19474572

Group type: EXPERIMENTAL
Intervention: Verbal repetition in patients with AD
Number of subjects: 130
Study: 16968142

Group type: EXPERIMENTAL
Intervention: Comprehensive, developmentally oriented, highly individualized intervention over a 2-year period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12719052

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine (postoperative infusion)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (postoperative infusion)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (postoperative infusion)
Number of subjects: 45
Study: 10805824

Group type: EXPERIMENTAL
Intervention: High-fiber diet (total, 50 g; 25 g of soluble fiber and 25 g of insoluble fiber)
Number of subjects: 13
Study: 9483708

Group type: EXPERIMENTAL
Intervention: Socially dominant subjects
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subordinate men
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: End of training
Number of subjects: 63
Study: 8347915

Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging with twice-daily dosing (group 3)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional packaging with twice-daily dosing (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No change in dosing or packaging (group 1)
Number of subjects: 31
Study: 2875927

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (200 mg three times daily)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 221
Study: 29676824

Group type: EXPERIMENTAL
Intervention: Cytisine with brief behavioural support
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Placebo with brief behavioural support
Number of subjects: 2388
Study: 27125590

Group type: EXPERIMENTAL
Intervention: Topical S. ebulus gel, applied three times a day for 4 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1% diclofenac gel, applied three times a day for 4 weeks
Number of subjects: 79
Study: 24896807

Group type: EXPERIMENTAL
Intervention: Kre-Celazine(®)
Number of subjects: 16
Study: 22772746

Group type: EXPERIMENTAL
Intervention: Home aftercare
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 130
Study: 20300778

Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution with 1% glucose (Group G)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Acetated Ringer's solution without glucose (Group R)
Number of subjects: 31
Study: 18525137

Group type: EXPERIMENTAL
Intervention: Tele-coaching intervention (10 sessions)
Number of subjects: 24
Study: 16112300

Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 101
Study: 12472703

Group type: COMPARATOR
Intervention: Caudal block (group C: n = 20; ropivacaine 0.2%, 1 ml.kg‐1 + clonidine 2 micro g.kg‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ilioinguinal-iliohypogastric nerve block (group I: n = 20; ropivacaine 0.2%, 0.4 ml.kg‐1 + clonidine 2 micro g.kg‐1)
Number of subjects: 40
Study: 10221346

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (enalapril maleate) alone (group I)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril maleate) plus spironolactone (25 mg/d) (group II)
Number of subjects: 18
Study: 7590642

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 150 micrograms desogestrel (EE/DG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol and 3-keto-desogestrel (EE/KDG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 0
Study: 2126985

Group type: EXPERIMENTAL
Intervention: Recombinant interferon gamma (rIFN gamma) at doses escalating from 0.01 mg/m2 to 5 mg/m2, given by intravenous bolus every 72 hours for 15 days
Number of subjects: 29
Study: 7025261

Group type: EXPERIMENTAL
Intervention: Carprofen 300 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 75 mg/d
Number of subjects: 0
Study: 30152252

Group type: EXPERIMENTAL
Intervention: Oral antibiotic treatment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Intravenous antibiotic treatment
Number of subjects: 400
Study: 27921448

Group type: EXPERIMENTAL
Intervention: Li maneuver
Number of subjects: 113

Group type: COMPARATOR
Intervention: Epley maneuver
Number of subjects: 113
Study: 26911112

Group type: EXPERIMENTAL
Intervention: Bone-setting manipulation (flexion top spin and lock bone-setting manipulation of cervical spine), treated once every two days for 20 days
Number of subjects: 320

Group type: COMPARATOR
Intervention: Manipulation of reposition cervical spine by rotation, treated once every two days for 20 days
Number of subjects: 320
Study: 23343564

Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) using 12-lead ECG and hand-held ECG recording for 2 weeks.
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) using hand-held ECG recording.
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Stepwise screening for atrial fibrillation (AF) leading to oral anticoagulation treatment.
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Known atrial fibrillation (AF) patients not on oral anticoagulation treatment.
Number of subjects: 848
Study: 22589265

Group type: EXPERIMENTAL
Intervention: CZP 200 mg
Number of subjects: 783
Study: 19359633

Group type: EXPERIMENTAL
Intervention: GRASP group (n=53)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (education protocol, n=50)
Number of subjects: 103
Study: 17294437

Group type: EXPERIMENTAL
Intervention: Molecular detection of luminal bacterial species
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mechanisms of innate immune and epithelial responses to bacteria
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Regulation of inflammation by innate and acquired immune cells
Number of subjects: 75
Study: 15452780

Group type: EXPERIMENTAL
Intervention: Detachable snares
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Epinephrine injection (0.01% solution)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Conventional snare polypectomy without preventive measures
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Detachable snares (in polyps >= 2 cm)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Epinephrine injection (in polyps >= 2 cm)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Conventional snare polypectomy without preventive measures (in polyps >= 2 cm)
Number of subjects: 488
Study: 11255206

Group type: EXPERIMENTAL
Intervention: Health Education Group (HEP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 105
Study: 9236425

Group type: EXPERIMENTAL
Intervention: End-systolic volume index (ESVI) measured at 90 to 180 minutes into thrombolytic therapy for MI
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Clinical variables tested in stepwise logistic regression analysis
Number of subjects: 41021